Physiopathology Study of the Microbiota Biodiversity of HIV Seropositive Patients
Completed
- Conditions
- HIV-1 Infection
- Interventions
- Other: Physiopathology study
- Registration Number
- NCT02116374
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Brief Summary
The bacterial diversity of HIV patients digestive microbiota seropositive is poorly understood, it remains to be defined.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
- Patient aged 18 or more.
- Patients with a confirmed diagnosis of HIV infection 1.
- Patient who signed an informed consent form.
- Patient affiliated or beneficiary of a social security system.
Exclusion Criteria
- Patient known to be suffering from inflammatory bowel disease (Crohn's disease or ulcerative colitis).
- Patient HIV-2 or HIV-1/HIV-2 co-infected
- Patient having received immunotherapy
- Patient participating in another research.
- Pregnant women, parturient or lactating person under guardianship, or deprived of liberty by a judicial or administrative decision.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description HIV-1 patients Physiopathology study -
- Primary Outcome Measures
Name Time Method Proportion and type of OTU (Operational Taxonomic Unit) assigned to the rank of phylum genus and species of bacteria in the intestinal microbiota of HIV-1 seropositive patients. Baseline
- Secondary Outcome Measures
Name Time Method Proportion and OTU types in the gastrointestinal microbiota of HIV-1 seropositive patients based on CD4, viral load, the Elite controller status, antiretroviral and antibiotic treatment and the existence of invasive bacterial infections. Baseline Transcriptomic analysis in the groups that present differences in the microbiota and analysis of lymphocyte populations Th17 and Treg. Baseline Proportion and OTU types in the gastrointestinal microbiota of HIV-1 seropositive patients compared to the general population Baseline Proportion and OTU types in the gastrointestinal microbiota of HIV-1 seropositive patients based on inflammation parameters (IL-6, TNF-a, IP-10), CRPus, CD14 and integrity of the epithelial barrier (I-FABP). Baseline
Trial Locations
- Locations (4)
Centre Henri Mondor
🇫🇷Creteil, France
Service de Médecine Interne et Immunologie Clinique
🇫🇷Le Kremlin Bicêtre, France
Service de maladies Infectieuses
🇫🇷Marseille, France
IHU Méditerranée Infection; Hôpital Nord, AP-HM
🇫🇷Marseille, France